Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Carcinomatosis 1Brain Neoplasms 1

Interventions

Radiotherapy 4Blood Specimen Collection 3Ultrasonography 2Temozolomide 2Radiosurgery 2Pemetrexed 2Exercise 2pembrolizumab 1lithium sulfate 1ipatasertib 1dactolisib 1aumolertinib 1aflutinib 1Zinc 1Surgery, Computer-Assisted 1Standard of Care 1Quality of Life 1Pliability 1Photic Stimulation 1Observation 1Neuropsychological Tests 1Moxibustion 1Metformin 1Mental Status and Dementia Tests 1Magnetic Resonance Imaging 1Lomustine 1Lithium 1Hypoglycemic Agents 1Ga(III)-DOTATOC 1Duloxetine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × aumolertinib × CNS × Clear all
NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Henan Cancer Hospital

Phase NA Unknown
60 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡